FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
